Haematologica

Article	Citations
Pediatric acute lymphoblastic leukemia	273
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia	99
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors	97
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia	97
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma	92
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial	83
Multiple myeloma: the (r)evolution of current therapy and a glance into future	80
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	78
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	74
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion	71
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	68
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide	65
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study	65
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition	64
History of hematopoietic cell transplantation: challenges and progress	63
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT	60
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria	58
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia	55
Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies	54
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis	54
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma	54
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients	52
Complement C5 inhibition in patients with COVID-19 - a promising target?	50
Post-mortem findings in vaccine-induced thrombotic thombocytopenia	47
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies	47

MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma	47
ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults	47
Targeting the tumor microenvironment in chronic lymphocytic leukemia	46
VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)	46
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS	45
Leukemic stem cells and therapy resistance in acute myeloid leukemia	45
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma	45
Potential targeting of FLT3 acute myeloid leukemia	44
The interactome of the N-terminus of band 3 regulates red blood cell metabolism and storage quality	43
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies	41
The clinical impact of the molecular landscape of acute myeloid leukemia	40
Red cell transfusion and alloimmunization in sickle cell disease	40
Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients	39
A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol	39
Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?	39
Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood s	38
Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy	38
Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial	37
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany	37
The molecular basis for the prothrombotic state in sickle cell disease	36
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines	36
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome	36
A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis	36
<i>DUX4r</i>, <i>ZNF384r</i> and <i>PAX5</i>-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch	36
Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York	36
Complement dysregulation is associated with severe COVID-19 illness	35
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis	35
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma	35
Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia	34
Unique ethnic features of <I>DDX41</I> mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia	33
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia	32
IgM monoclonal gammopathies of clinical significance: diagnosis and management	32
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape	32
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation	32
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy	31
No evidence of hemoglobin damage by SARS-CoV-2 infection	31
Hemostatic alterations in COVID-19	30
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?	30
Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy	29
Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia	29
Successful pregnancies after transplantation of ovarian tissue retrieved and cryopreserved at time of childhood acute lymphoblastic leukemia – A case report	29
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter	28
Stored blood has compromised oxygen unloading kinetics that can be normalized with rejuvenation and predicted from corpuscular side-scatter	28
COVID-19 and sickle cell disease	28
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality	28
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study	28
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma	27
Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies	27
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	27
Marginal zone lymphoma: present status and future perspectives	27

Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease	27
Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways	26
Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion	26
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study	26
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study	26
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leuke	26
Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect	26
Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19	25
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study	25
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia	25
Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome	25
Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish	25
Aging of human hematopoietic stem cells is linked to changes in Cdc42 activity	24
Endothelial damage and dysfunction in acute graft-versus-host disease	24
Deregulation of JAK2 signaling underlies primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphoma	24
The present and future of measurable residual disease testing in acute myeloid leukemia	24
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia	24
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma	24
Treatment of drug-induced immune thrombocytopenias	24
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute l	24
Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease	23
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag	23
Novel immunotherapies in multiple myeloma – chances and challenges	22
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde	22
Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease	22
Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations	22
A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia	22
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective	21
CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients	21
Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype	21
Prevention and management of secondary central nervous system lymphoma	21
<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)	21
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study	21
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)	21
Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis	20
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia	20
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma	20
CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity	20
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia	20
Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma	20
Translational and clinical advances in acute graft-versus-host disease	20
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis	20
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis	20
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results	19
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients	19
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies	19
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas	19
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model	19
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study	19
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies	19
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration	19
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia	19
Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine	19
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing	19
Towards manufactured red blood cells for the treatment of inherited anemia	19
PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia	18
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute	18
The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma	18
Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets	18
Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents	18
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab	18
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial	18
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panel	18
The TRPV2 channel mediates Ca2+ influx and the Δ9-THC-dependent decrease in osmotic fragility in red blood cells	18
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination	18
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients	18
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation	18
The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis	18
The Hsp70 chaperone system: distinct roles in erythrocyte formation and maintenance	18
How I diagnose and treat chronic myelomonocytic leukemia	17
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma	17
Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia	17
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib	17
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome	17
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study	17
Protein-L-isoaspartate O-methyltransferase is required for <i>in vivo</i> control of oxidative damage in red blood cells	17
Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis	17
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project	17
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia	17
Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing	17

The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial	17
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis	16
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications	16
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients	16
Baseline SUV<sub>max</sub> is related to tumor cell proliferation and patient outcome in follicular lymphoma	16
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	16
Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia	16
Perforin gene variant A91V in young patients with severe COVID-19.	16
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients	16
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis	16
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation	16
Crucial role of hematopoietic <i>JAK2</i> V617F in the development of aortic aneurysms	16
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia	16
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications	16
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results	16
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice	16
Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse	16
A novel classification of hematologic conditions in patients with Fanconi anemia	16
Differentiation therapy of myeloid leukemia: four decades of development	16
Dominance of an <i>UBA1</i> mutant clone over a <i>CALR</i> mutant clone: from essential thrombocytemia to VEXAS.	16
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential	16
Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy	16
Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis- related graft failure and disseminated bacillus Calmette-Guérin infection	15
<i>DUSP22</i> rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma	15
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial	15
Genotype-phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort	15
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome	15
Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes	15
Post-translational polymodification of β1-tubulin regulates motor protein localization in platelet production and function	15
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	15
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia	15
Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial	15
Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation	15
SARS-CoV-2 infection in aplastic anemia	15
Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia	15
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities	15
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?	15
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial	15
Mitochondrial ATP generation in stimulated platelets is essential for granule secretion but dispensable for aggregation and procoagulant activity	15
Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation	15
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06	15
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study	15
Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome	15
Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34<sup>+</sup> cord blood hematopoietic stem cells using a clinically applicable lentiviral vector	15
Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study	15
New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia	14
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?	14
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study	14
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA	14
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias	14
Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden	14
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma	14
Prospects in the management of patients with follicular lymphoma beyond first-line therapy	14
The “7+3” regimen in acute myeloid leukemia	14
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma	14
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas	14
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study	14
Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia	14
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis	14
Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency	14
GNE-related thrombocytopenia: evidence for a mutational hotspot in the ADP/substrate domain of the GNE bifunctional enzyme	13
Immunologic characterization of COVID-19 patients with hematological cancer	13
A risk score based on real-world data to predict early death in acute promyelocytic leukemia	13
High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL	13
Fusion gene detection by RNA-sequencing complements diagnostics of acute myeloid leukemia and identifies recurring <i>NRIP1-MIR99AHG</i> rearrangements	13
A mutation in the iron-responsive element of <i>ALAS2</i> is a modifier of disease severity in a patient suffering from <i>CLPX</i> associated erythropoietic protoporphyria	13
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma	13
Time for an individualized approach to first-line management of follicular lymphoma	13
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study	13
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma	13
<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation	13
Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate	13
Use of the HLA-B leader to optimize cord blood transplantation	13
Hypoxia-inducible erythropoietin expression: details matter	13
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study	13
Mobilization efficiency is critically regulated by fat via marrow PPARδ	13
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia	13
Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way	13
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphom	13
Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants	13
Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T-cell leukemia	13
Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells <i>in vivo</i>	12
Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis	12
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy	12
Pathogenetic and clinical study of a patient with thrombocytopenia due to the p.E527K gain-of-function variant of SRC	12
Exosome-driven lipolysis and bone marrow niche remodeling support leukemia expansion	12
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers	12
A prognostic index predicting survival in transformed Waldenström macroglobulinemia	12
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective	12
Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations	12
Pure erythroid leukemia is characterized by biallelic <i>TP53</i> inactivation and abnormal p53 expression patterns in <i>de novo</i> and secondary cases	12
Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells	12
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial	12
Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia	12
Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC)	12